Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tylenol Sore Throat Line Extension To Debut In October

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer Healthcare will expand the Tylenol analgesic/cough/cold brand in October with the launch of Tylenol Sore Throat liquids. Each dose provides 1,000 mg acetaminophen.

You may also be interested in...



Generic Nicotine Replacement Products Start To Smoke In 2000

Private label OTC smoking cessation products thrived in 2000, their first full year on the food, drug and mass market, recording sales well over $100 mil. and capturing nearly a 20% dollar share, according to data from Information Resources, Inc. (Chicago).

Generic Nicotine Replacement Products Start To Smoke In 2000

Private label OTC smoking cessation products thrived in 2000, their first full year on the food, drug and mass market, recording sales well over $100 mil. and capturing nearly a 20% dollar share, according to data from Information Resources, Inc. (Chicago).

Generic Nicotine Replacement Products Start To Smoke In 2000

Private label OTC smoking cessation products thrived in 2000, their first full year on the food, drug and mass market, recording sales well over $100 mil. and capturing nearly a 20% dollar share, according to data from Information Resources, Inc. (Chicago).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel